T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
about
Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma.Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.An engineered protein antagonist of K-Ras/B-Raf interaction.Tools to define the melanoma-associated immunopeptidome.Immunotherapy for pancreatic cancer: present and future.HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.Applications of Immunogenomics to Cancer.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.Targeting neoantigens to augment antitumour immunity.The Heterocellular Emergence of Colorectal CancerMechanisms of Resistance in Multiple Myeloma.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Tuning cancer fate: the unremitting role of host immunity.Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Harnessing the immune response to target tumors.Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Immunotherapy in gastrointestinal cancersImmunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies.Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?Fall of the mutants: T cells targeting BCR-ABL.It's a long way to the top (if you want to personalize immunotherapy)Awakening immunity against cancer: a 2017 primer for clinicians.KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer.'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology.Molecular genetics and cellular events of K-Ras-driven tumorigenesis.Human Pluripotent Stem Cells to Produce Cell-based Cancer Immunotherapy.Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment.Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
P2860
Q33798623-50513C1F-D9B1-4443-AA31-4CE30666CA12Q33806351-1FB0E220-D266-48F9-ABB1-B2421497D134Q33913077-9B3B2DA5-C286-4F38-B34C-1C7B3AA8E247Q33918529-7B678939-61C9-499F-BD6B-1231FA94015BQ38650013-8D0968A9-CE75-4E99-B4E6-26DB3BE19887Q38673158-D6971244-536C-4C77-835B-43C3CE7B6B77Q38706874-47253A3B-DFDA-4CD7-96DF-FBA024D8DD87Q39057617-C14D6B08-951E-4B59-8D5D-8E3E00369B92Q39120155-653E5557-62C5-4840-A278-7A50938576FEQ39130420-F45D1D1F-02F5-4151-A728-D2200EB2C5C9Q39130451-EAE80B7C-26CE-4F65-9DD8-AAA13A45753EQ39136403-9615422C-3AEF-4F09-B554-9E5C23983980Q39149196-3191B3AE-1B01-49AD-9EE1-ECC34FA7B7E6Q39152114-5A0E614C-7579-4B02-AFDA-0AABF785EDCBQ39185604-0DB402F6-1659-4D59-AE25-23ADDC5BFA6FQ39194733-431CE550-280B-4BEC-80B5-683E86AA3B9CQ39239026-175D15D8-50B6-4E79-9D51-7F18999B7751Q39243064-D7510CBF-63D4-4905-9140-BE696831FC69Q39246685-D0F8D819-8377-4236-8479-35AD7214E6C6Q39377265-FF4E7139-2115-41D3-9CC4-15332597D528Q39418546-568D09E7-3671-4D07-A89C-A2696E2C9E15Q39438805-EBF6215F-E865-48A5-A0F8-A8728846A018Q39453597-CE3EC669-828C-459F-94D2-59D6BEA8BCF7Q41183874-9792EF7F-0362-4132-8BD7-1F0ED485F5D6Q41571576-36794053-78E2-4EF3-B095-04C723A4BE69Q41673084-01DF51A6-F1FD-4D86-995A-7C1CBE790EBDQ41928232-2A278E33-4E56-4004-BFDB-ABA12FE34ACCQ42324198-7502BD2A-133F-46CE-A2D2-03435EAB04B7Q42330130-C79C3FD1-1214-48C3-A143-9947B0DCB702Q42347636-4470088F-E48D-44C8-8E4E-BA56BDAC1482Q42778262-E804DCF9-4EFC-45E5-BDDE-E18F5DF6B94AQ45718710-955A7DDC-D939-4D3F-BCF1-9BFA9C19F9F5Q45875006-083A36D9-5DB9-410D-885C-5C1C72B54127Q46056233-CF0842AE-9F2D-439F-8CEA-EBFDD7ACFE7DQ46277416-B4F28F1A-4512-4DF0-B726-038C93B24A5EQ46350666-90AF722B-BEB0-4282-A034-B4F89295F903Q46512368-62281353-DCD3-4D96-A082-81E41B26D216Q47124785-AF62B223-D71D-4747-90F8-F7751DD1954DQ47133741-B6D3C4E8-96D6-4119-9717-0734AD8E53C9Q47150991-0EC60C58-EE1D-4886-B88C-A34212F969C6
P2860
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
@ast
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
@en
type
label
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
@ast
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
@en
prefLabel
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
@ast
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
@en
P2093
P2860
P356
P1476
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
@en
P2093
Anna Pasetto
Eric M Groh
Isaac R Kriley
Jared J Gartner
Paul F Robbins
Satyajit Ray
Steven A Rosenberg
Todd D Prickett
P2860
P304
P356
10.1056/NEJMOA1609279
P407
P50
P577
2016-12-01T00:00:00Z